Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ampio Pharmaceuticals Inc AMPE

Healthcare
Ampio Pharmaceuticals, Inc. is a drug discovery and development company. The Company is focused on combining scientific, clinical, and manufacturing capabilities to develop therapies aimed at treating conditions for which limited treatment options exist.

Recent & Breaking News (OTCPK:AMPE)

Ampio Pharmaceuticals, Inc. Announces Public Offering of Common Stock

PR Newswire February 24, 2014

Ampio Completes Enrollment and Dosing in 2nd Pivotal Clinical Trial for Ampion(TM) (The STEP Study) for Its FDA Biological License Application (BLA)

PR Newswire February 18, 2014

Ampio Announces Positive Preliminary Biochemical Findings from the Synovial Fluid of the Knees Treated in the SPRING Study

PR Newswire February 13, 2014

Ampio Pharmaceuticals announces publication of findings for its lead product, Ampion(TM) in the journal PLOS ONE

PR Newswire February 4, 2014

Ampio Pharmaceuticals Breaks Ground on Construction of Ampion(TM) Manufacturing Facility

PR Newswire January 15, 2014

Ampio Injects First Patients in 2nd Phase III, Pivotal Clinical Trial for Ampion(TM)(The STEP Study) for Its FDA Biological License Application (BLA).

PR Newswire January 13, 2014

Luoxis Awarded ISO 13485:2003 and ISO 9001:2008 Certifications

PR Newswire January 9, 2014

Luoxis Establishes Study Collaborations with Two Research Centers in Oxidative Stress

PR Newswire January 6, 2014

Ampio Pharmaceuticals Leases New Facility in Denver Tech Center

PR Newswire December 16, 2013

Ampio Pharmaceuticals Spins-Off Sexual Dysfunction Business

PR Newswire December 13, 2013

Two Prominent Scientists Join Ampio Pharmaceuticals Scientific Advisory Board (SAB)

PR Newswire December 3, 2013

Ampio Receives FDA Confirmation that The Spring Study is Pivotal and Will Initiate the Final Pivotal Trial for Ampion(TM) Biological License Application (BLA)

PR Newswire December 2, 2013

Ampio Responds to Levi & Korsinsky, LLP Press release/solicitation

PR Newswire November 19, 2013

AMPIO PHARMACEUTICALS, INC. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Ampio Pharmaceuticals, Inc.

PR Newswire November 18, 2013

Ampio Pharmaceuticals to Present at Upcoming Investor Conference

PR Newswire November 15, 2013

Ampio Pharmaceuticals Reports Positive Results in the Extended Spring study of Osteoarthritis of the Knee Following a Single Intra-articular Injection of Ampion(TM)

PR Newswire November 4, 2013

Ampio Pharmaceuticals, Inc. States that its Policy is Not to Comment on Unusual Market Activity

PR Newswire October 25, 2013

Ampio Pharmaceuticals, Inc. Announces Positive Results from Independent Panel Review of the Interim Analysis of the Optina(TM) Trial for Diabetic Macular Edema

PR Newswire October 7, 2013

Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of company's third US patent for its oxidation-reduction potential diagnostic platform

PR Newswire October 1, 2013

Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial

PR Newswire September 30, 2013